Long-Term Celgene (CELG) Investors: Johnson Fistel Investigates Celgene Corporation; Encourages Long-Term Investors to Contact the Firm
Summary
The complaint alleges that during the Class Period, defendants made false and misleading statements and failed to disclose adverse information regarding Celgenes business and the prospects for its drug products.As a result of these false statements and omissions, the price of Celgene stock was artificially inflated during the Class Period to over $145 per share.On October 19, 2017, the Company revealed that it would be abandoning GED-0301, discontinuing ongoing trials, and would record a $1.6 billion impairment charge as a result of the drugs failure.Then, after the market closed on February 27, 2018, Celgene disclosed that it had received a refusal to file letter from the FDA in connection with the Companys NDA for Ozanimod.If you are a Celgene shareholder continuously holding shares before September 12, 2016 , and are interested in learning more about your legal rights and remedies, please contact Jim Baker ( jimb@johnsonfistel.com ) at 619-814-4471.